Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And when the value is there, we continue to be in a strong position to strike |
| Non-GAAP adjusted EBITDA was a record $104.2 million for the fourth quarter, up 36% year-over-year and a record $367 million for full-year 2023, up 38% |
| As we build a leading diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, we strive to do good as we do well |
| So first, what I'd say is we have very strong access in commercial and Part D for Xtampza |
| We are proud to provide this opportunity to students who have demonstrated financial need, academic achievement, leadership, community service and a commitment to learning as they pursue a career in STEM |
| That gives us the ability to really go after and try to achieve new wins for the product |
| Key accomplishments in 2023 include: we delivered record revenue and record adjusted EBITDA; we returned BELBUCA to sequential quarterly prescription growth starting in Q2 2023, and saw year-over-year quarterly growth in Q3 and Q4 |
| So we really have a strong view that we'll grow prescriptions this year, and BELBUCA is certainly a product that's worthy of that |
| First off with Xtampza, the thing that we are confident in is our ability to continue to grow revenue as we move forward through 2033 with the asset |
| Our accomplishments in 2023 position the organization for success in 2024 and bolster our outlook in 2025 and 2026 |
| In closing, I'm proud of our commercial accomplishments in 2023 and focused on achieving our objectives in 2024 through operational execution |
| And by doing that, I'm confident we have the ability to grow organically where we have access, and then we'll see, as Joe said, what happens with the payer as we move forward |
| We successfully renegotiated contracts, representing 30% of all Xtampza ER prescriptions, maintaining access and improving rebates in 57% of plans |
| We expect BELBUCA to benefit from improved commercial execution, the successful renegotiation of a major Medicare Part D contract and the addition of a new Part D plan, representing approximately one million covered lives |
| Look, what I can tell you, number one, is the BDSI acquisition for Collegium was an excellent deal and one that the team has done an exceptional job executing around |
| Our commercial accomplishments in 2023 position BELBUCA for growth in 2024 |
| The new patient population exclusivity for Nucynta, together with the potential pediatric extension for the Nucynta franchise, bolster our outlook in 2025 and 2026 |
| Our record financial performance and operational achievements in 2023 position the organization for success in 2024 and beyond |
| We expect to deliver record revenue, adjusted EBITDA, free cash flow and net income in 2024 |
| The key thing that I would emphasize in closing here is what we are confident in is the ability, whether it be through the addition of new profitable contracts that would be a catalyst to volume and/or as we continue to renegotiate contracts moving forward, that we'll be able to continue to grow Xtampza ER revenue |
| We are encouraged by the BELBUCA prescription growth we saw in the fourth quarter of 2023, and we expect to see full-year prescription growth in 2024, along with gross-to-net improvement |
| This is a major accomplishment that will fuel Xtampza ER revenue growth in 2024 |
| We continue, as we execute versus the core business and financially what we're setting out to do, along with the improvement each quarter on the balance sheet to further strengthen our position |
| Xtampza ER has strong data in its label differentiating it from OxyContin, and it has superior access in both commercial and Medicare Part D |
| In 2023, we delivered record revenue, driven by significant gross-to-net improvement |
| The new population exclusivity achieved for Nucynta in 2023 and the anticipated pediatric extensions for the franchise in 2024, along with the reduction in the royalties we pay on Nucynta franchise sales from 14% to 7% beginning on June 27, 2025, bolster our outlook for the franchise in 2025 and 2026 |
| Stronger commercial execution drove sequential quarterly growth beginning in the second quarter of 2023 |
| It's the right thing to do and, if successful will serve as a catalyst for growth in 2025 and beyond |
| I am confident that we are well positioned to deliver on our financial and capital deployment objectives |
| So we -- for the right opportunity, if we have conviction that it can be $150 million plus, then we're in a great position to execute around that |
| Statement |
|---|
| Nucynta franchise net revenue was $46.9 million in the fourth quarter, down 2% year-over-year and $190.8 million in 2023, up 3% year-over-year |
| I think so far this year, we've seen about a 6% prescription erosion for Xtampza |
| GAAP operating expenses were $32.9 million in the fourth quarter, down 13% year-over-year |
| We do expect some pressure on Nucynta franchise revenue in 2024 because of the American Recovery Act eliminating the Medicaid cap |
| Non-GAAP adjusted operating expenses were $25.9 million in the fourth quarter, down 20% year-over-year |
| We think it is very challenging to achieve the doses of BELBUCA or all doses without infringing upon the IP |
| For 2023, GAAP operating expenses were $159.2 million, down 10% year-over-year |
| Our focus with Xtampza ER in 2024 is on challenging the status quo with health care professionals |
| You are cautioned that such forward-looking statements involve risks and uncertainties, including and without limitation, the risk that we may not be able to successfully commercialize our products, that we may incur significant expense and that we may not prevail in current or future litigation pertaining to our business |
| And how we do that is by challenging the status quo |
Please consider a small donation if you think this website provides you with relevant information